

( (S (S-TPC-1 (NP-SBJ An experimental vaccine)
	      (VP can
		  (VP alter
		      (NP (NP the immune response)
			  (PP of
			      (NP (NP people)
				  (VP infected
				      (NP *)
				      (PP-CLR with
					      (NP the AIDS virus)))))))))
     ,
     (NP-SBJ a prominent U.S. scientist)
     (VP said
	 (SBAR 0
	       (S *T*-1)))
     .))
( (S (ADVP However)
     ,
     (NP-SBJ that)
     (VP does n't
         (VP mean
             (SBAR 0
                   (S (NP-SBJ they)
                      (VP can
                          (VP benefit
                              (PP-CLR from
				      (NP the vaccine))))))))
     .))
( (S (NP-SBJ-1 Its effectiveness)
     (VP ca n't
         (VP be
             (VP determined
                 (NP *-1)
		 (SBAR-TMP until
			   (S (NP-SBJ-2 a large clinical trial)
			      (VP is
				  (VP undertaken
				      (NP *-2)
				      (PP by
					  (NP-LGS the Army))
				      (PP-TMP in
					      (NP January))))))
		 ,
		 (PP according
		     (PP to
			 (NP (NP Robert Redfield)
			     ,
			     (NP (NP chief)
				 (PP of
				     (NP acquired immune deficiency syndrome research))
				 (PP-LOC at
					 (NP (NP Walter Reed Army Institute)
					     (PP of
						 (NP Research)))))))))))
     .))
( (S (NP-SBJ (NP (NP Dr. Redfield 's)
		 report)
	     (PP on
                 (NP (NP early experiments)
                     (VP using
                         (NP (NP an AIDS vaccine)
                             (VP made
                                 (PP by
                                     (NP-LGS (NP MicroGeneSys Inc.)
					     (PP-LOC of
						     (NP (NP West Haven)
							 ,
							 (NP Conn.)))))))))))
     ,
     (VP came
	 (PP-LOC-CLR at
		     (NP (NP a meeting)
			 (PP of
			     (NP AIDS vaccine researchers))))
	 (PP-LOC in
		 (NP Florida))
	 (NP-TMP late Monday))
     .))
( (S (NP-SBJ-2 (NP The vaccine)
               ,
               (NP VaxSyn HIV-1)
               ,)
     (VP has
         (VP been
             (VP (ADVP-MNR safely)
                 given
                 (NP *-2)
                 (PP-DTV to
			 (NP (NP 14 people)
			     ,
			     (SBAR (WHNP-3 some
					   (WHPP of
						 (WHNP whom)))
				   (S (NP-SBJ *T*-3)
				      (VP are
					  (VP experiencing
					      (NP (NP substantial increases)
						  (PP-LOC in
							  (NP certain antibodies))))))))))))
     .))
( (S ``
     (S-TPC-2 (NP-SBJ-1 The conventional wisdom)
	      (VP used
		  (S (NP-SBJ *-1)
		     (VP to
			 (VP be
			     (SBAR-PRD that
				       (S (NP-SBJ you)
					  (VP could n't
					      (VP modify
						  (NP (NP the immune response)
						      (PP of
							  (NP an infected individual)))
						  ''
						  (PP-MNR by
							  (S-NOM (NP-SBJ *)
								 (VP innoculating
								     (NP them)
								     (PP-CLR with
									     (NP synthetic viral proteins))))))))))))))
     ,
     (NP-SBJ Dr. Redfield)
     (VP said
	 (SBAR 0
	       (S *T*-2)))
     .))
( (S ``
     (NP-SBJ We)
     (VP 've
         (VP demonstrated
             (SBAR that
                   (S (NP-SBJ you)
                      (VP can 
			  (VP *?*)))))) 
     . ''))
( (S (NP-SBJ He)
     (VP said
         (SBAR 0
               (S (NP-SBJ certain volunteers)
                  (VP developed
                      (NP (NP (NP kinds)
                              (PP of
                                  (NP antibodies)))
                          (VP associated
                              (NP *)
                              (PP-CLR with
				      (NP early AIDS))))))))
     .))
( (S (S-TPC-1 (NP-SBJ (NP Other antibodies)
		      (VP sparked
			  (NP *)
			  (PP by
			      (NP-LGS the preparation))))
	      (VP are
		  (PP-PRD of
			  (NP (NP a sort)
			      (ADJP rarely present
				    (PP in
					(NP large quantities))
				    (PP in
					(NP (ADJP infected or ill) individuals)))))))
     ,
     (NP-SBJ he)
     (VP added
	 (SBAR 0
	       (S *T*-1)))
     .))
( (S (NP-SBJ (NP One)
	     (PP of
		 (NP (NP the mysteries)
		     (PP of
			 (NP AIDS)))))
     (VP remains
	 (SBAR-NOM (WHADVP why)
		   (S (NP-SBJ infected people)
		      (VP (VP produce
			      (NP (NP large quantities)
				  (PP of
				      (NP antibodies))))
			  , 
			  but
			  (VP deteriorate
			      (ADVP nonetheless))))))
     .))
